Lillys insight was that GIP receptor agonism (rather than just endogenous GIP signalling) might overcome this resistance and add metabolic benefits complementary to GLP-1 agonism
Combined with the GLP-1-mediated improvements in insulin sensitivity and the GIP-mediated changes in lipid metabolism, the triple agonist creates conditions under which the liver clears accumulated fat at rates never before observed in clinical settings
This article examines the evidence, explores possible explanations for skin changes, and provides practical guidance on when to seek medical advice
Well, the GLP-1 agonists provide us with a whole new way of thinking about this risk-benefit analysis
We recently launched our in-app chatbot, Melody, powered by the worlds most powerful AI technology
The approval is backed by data from Part 1 of the Phase III RUBY trial, where treatment with the Jemperli regimen led to a 31% reduction in risk of death compared to chemotherapy alone